How biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2013-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2012.04297.xPMID 22506644PMCID PMC3731600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

  2013cited by this paper
• Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial

  2012cited by this paper
• Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

  2012cited by this paper
• Activation of the NLRP 3 Inflammasome

  2012cited by this paper
• Type 2 diabetes as an inflammatory disease

  2011cited by this paper
• Genetics of type 2 diabetes: pathophysiologic and clinical relevance

  2011cited by this paper
• Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance?

  2011cited by this paper
• Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

  2011cited by this paper
• Globalization of Diabetes

  2011cited by this paper
• Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling

  2011cited by this paper
• Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

  2011cited by this paper
• Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.

  2011cited by this paper
• NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

  2010cited by this paper
• The inflammasomes.

  2010cited by this paper
• The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes

  2010cited by this paper
• Prevalence of diabetes among men and women in China.

  2010cited by this paper
• Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation.

  2010cited by this paper
• Prevalence of diabetes among men and women in China.

  2010cited by this paper
• The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance

  2010cited by this paper
• Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

  2010cited by this paper
• The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity.

  2010cited by this paper
• Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes

  2010cited by this paper
• Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

  2010cited by this paper
• Prevalence of diabetes among men and women in China.

  2010cited by this paper
• NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease

  2010cited by this paper
• Thioredoxin-interacting protein links oxidative stress to inflammasome activation

  2010cited by this paper
• Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes.

  2009cited by this paper
• Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

  2009cited by this paper
• Islet-associated macrophages in type 2 diabetes

  2009cited by this paper
• Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

  2009cited by this paper
• Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

  2009cited by this paper
• Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes

  2009cited by this paper
• IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

  2008cited by this paper
• Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

  2007cited by this paper
• Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.

  2007cited by this paper
• Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels

  2007cited by this paper
• Increased Number of Islet-Associated Macrophages in Type 2 Diabetes

  2007cited by this paper
• Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

  2007cited by this paper
• Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets.

  2006cited by this paper
• Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice.

  2006cited by this paper
• Low Concentration of Interleukin-1β Induces FLICE-Inhibitory Protein–Mediated β-Cell Proliferation in Human Pancreatic Islets

  2006cited by this paper
• Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes

  2006cited by this paper
• Type 2 diabetes-a matter of beta-cell life and death?

  2005cited by this paper
• Type 2 Diabetes-a Matter of ß-Cell Life and Death?

  2005cited by this paper
• Interleukin-1 Receptor Signaling Mediates Atherosclerosis Associated With Bacterial Exposure and/or a High-Fat Diet in a Murine Apolipoprotein E Heterozygote Model: Pharmacotherapeutic Implications

  2004cited by this paper
• Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.

  2003cited by this paper
• Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

  2003cited by this paper
• Obesity is associated with macrophage accumulation in adipose tissue.

  2003cited by this paper
• Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

  2002cited by this paper
• Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes.

  1999cited by this paper
• Type 2 Diabetes: When Insulin Secretion Fails to Compensate for Insulin Resistance

  1998cited by this paper
• Interleukin-1 receptor antagonist: role in biology.

  1998cited by this paper
• Interleukin-1 (cid:1) -Induced Insulin Resistance in Adipocytes through Down-Regulation of Insulin Receptor Substrate-1 Expression

  year unknowncited by this paper

• Macrophages, Chronic Inflammation, and Insulin Resistance

  2022cites this paper
• Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes.

  2022cites this paper
• Epigenetic regulation of inflammation in insulin resistance.

  2022cites this paper
• Effect of Hydrolyzed Bird’s Nest on β-Cell Function and Insulin Signaling in Type 2 Diabetic Mice

  2021cites this paper
• Molecular mechanisms from insulin-mimetic effect of vitamin D: treatment alternative in Type 2 diabetes mellitus.

  2021cites this paper
• Association between IL-1B (-511)/IL-1RN (VNTR) polymorphisms and type 2 diabetes: a systematic review and meta-analysis

  2021cites this paper
• Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions

  2020cites this paper
• Recent updates on obesity treatments: available drugs and future directions.

  2020cites this paper
• The Immune System and Inflammation in Type 2 Diabetes

  2019cites this paper
• Platelets as Potent Signaling Entities in Type 2 Diabetes Mellitus.

  2019cites this paper
• RETRACTED ARTICLE: The effect of zinc and vitamin E cosupplementation on metabolic status and its related gene expression in patients with gestational diabetes

  2018cites this paper
• Aging and the Inflammasomes.

  2018cites this paper
• Interleukin-1 Beta—A Friend or Foe in Malignancies?

  2018cites this paper
• Appetite Changes Reveal Depression Subgroups with Distinct Endocrine, Metabolic, and Immune States

  2018cites this paper
• Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity

  2017cites this paper
• Inflammasomes and type 2 diabetes: An updated systematic review.

  2017cites this paper
• Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation

  2016influential citation
• Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy

  2016cites this paper
• Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes.

  2016cites this paper
• A Bioluminescence Sensor of NLRP 3 Inflammasome Activation

  2016cites this paper
• Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment

  2016cites this paper
• Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation

  2016cites this paper
• TITLE: eNAMPT-monomer plays an important role in development of experimental diabetes in mice and represents a potential target for treatment of type 2 diabetes

  2016cites this paper
• LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro

  2016cites this paper
• Various Effects of Omega 3 and Omega 3 Plus Vitamin E Supplementations on Serum Glucose Level and Insulin Resistance in Patients with Coronary Artery Disease

  2016cites this paper
• A bioluminescence sensor of NLRP3 inflammasome activation

  2016cites this paper
• Combined association analysis of interleukin 1-receptor antagonist (IL-1RN) variable number of tandem repeat (VNTR) and Haptoglobin 1/2 polymorphisms with type 2 diabetes mellitus risk

  2016cites this paper
• Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat

  2015cites this paper
• Mechanisms Linking Inflammation to Insulin Resistance

  2015cites this paper
• Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

  2015cites this paper
• Mesenchymal Stem Cell‐Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation

  2015cites this paper
• Molecular and physiological roles of Pellino E3 ubiquitin ligases in immunity

  2015cites this paper
• Dietary Exposures Contribute to Different Diseases through the Microenvironment

  2015cites this paper
• The E3 ubiquitin ligase Pellino3 protects against obesity-induced inflammation and insulin resistance.

  2014cites this paper
• Anti-inflammatory role of GLP-1 and the effect of gastric bypass on diabetes- and obesity-associated inflammation

  2014cites this paper
• Inflammasomes.

  2014cites this paper
• Specific inflammasomes in complex diseases.

  2013cites this paper
• Biological therapies: a long way on from Jenner.

  2013cites this paper
• Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes

  2012cites this paper
• Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes

  2012cites this paper